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Abstract: Lung cancer, the leading cause of mortality in both men and women in the United States, is largely diagnosed 
at its advanced stages that there are no effective therapeutic alternatives. Although tobacco smoking is the well established 
cause of lung cancer, the underlying mechanism for lung tumorigenesis remains poorly understood. An important event in 
tumor development appears to be the epigenetic alterations, especially the change of DNA methylation patterns, which in-
duce the most tumor suppressor gene silence. In one scenario, DNA methyltransferase (DNMT) that is responsible for 
DNA methylation accounts for the major epigenetic maintenance and alternation. In another scenario, DNMT itself is 
regulated by the environment carcinogens (smoke), epigenetic and genetic information. DNMT not only plays a pivotal 
role in lung tumorigenesis, but also is a promising molecular bio-marker for early lung cancer diagnosis and therapy. 
Therefore the elucidation of the DNMT and its related epigenetic regulation in lung cancer is of great importance, which 
may expedite the overcome of lung cancer. 
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1. INTRODUCTION 
  Lung cancer is the leading cause of mortality in both men 
and women worldwide. Currently, one in four deaths in 
America is owed to cancer. In 2008, there were 215,020 new 
cases of lung cancer, accounting for 15.0% of all new cancer 
cases; estimated death rate of lung cancer is expected to ac-
count for 28.6% of all cancer deaths [1,2]. 
  Lung cancer can be divided into two major histopa-
thological groups: non-small-cell lung cancer (NSCLC) and 
small-cell lung cancer (SCLC) (Fig. 1). About 80%~85% of 
lung cancers are NSCLC, which can be subdivided into ade-
nocarcinomas, squamous cell, and large-cell undifferentiated 
carcinoma. Squamous cell carcinoma (SC) and adenocarci-
noma (AC) are the most prominent types. SCLC accounts for 
just 15%~20% of all lung cancers and is far more aggressive 
than NSCLC. SCLC is split into different types depending 
on which cells in the lungs are affected by the cancer: small 
cell carcinoma (the most prominent type), mixed small cell 
carcinoma and combined small cell carcinoma. Besides the 
two major types of lung cancer there are other types of tumor 
which can appear in the lungs, and some of these are benign 
[2].  
  Epigenetics refers to a change in gene that is heritable 
(i.e. can be passed on through cell division) but is not in-
volved in a change in DNA sequence. This is in contrast with 
true genetic alterations [3-5]. Epigenetic processes include 
genomic imprinting [6], gene silencing [7,8], x-chromosome 
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inactivation [9], reprogramming in transferred nuclei [10, 
11] and some elements of carcinogenesis [12]. Epigenetic 
mechanisms play a crucial role in regulation of gene expres-
sion by affecting chromatin accessibility. DNA methylation 
catalyzed by specific DNA methyltransferase (DNMT) rep-
resents an important mechanism for the epigenetic control of 













Fig. (1).  Types and percentages of lung cancer. SC: squamous 
lung cancer; AC: adenocarcinomas; LC: large cell undifferentiated 
carcinomas; SCC: small cell carcinomas; MSC: mixed small cell 
carcinomas; CSC: combined small cell carcinomas; OT: other 
types. 
 
  This review focuses on the up and down stream of DNA 
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CpG dinucleotide context. Normally, 99% sequence of the 
entire genome is rarely with CpG site, only about 1% se-
quence is CpG rich, so-called CpG islands. Human genome 
contains 29000 CpG islands [14] and approximately half the 
CpG islands were often associated with promoter regions, 
and half the promoter regions in human genome possess 
these islands [15]. As for the non-CpG islands containing 
promoters, they bear other methylation patterns. Accumulat-
ing investigations have demonstrated that lung cancer devel-
opment is linked with aberrant DNA methylation patterns, 
which can be characterized as global genome hypomethyla-
tion accompanied by regional hypermethylation [16-18]. 
While global genome hypomethylation may be associated 
with the induction of chromosome instability (a cellular state 
characterized by an increased rate of genetic changes, includ-
ing DNA sequence changes, aneuploidy, chromosome trans-
locations, and/or gene amplication), gene-specific hyper-
methylation is known to be associated with the inactivation 
of various pathways involved in tumorigenic process induc-
ing DNA repair, cell cycle regulation, inflammatory/stress 
response and apoptosis, thus the aberrant methylation pat-
terns play a key role in epigenetic regulation of lung tumori-
genesis [19-22]. At the moment, more and more researchers 
focus on the DNMT regulation area, and the proposal and 
carrying out of Epigenomic Project (contrast to the Human 
Genome Project) has put the epigenetic mechanism of lung 
tumorigenesis to a such hot status, and surely expedite the 
clarification of DNMTs induced epigenetic disturbance 
mechanism for lung tumorigenesis and progression. 
2. OVERVIEW OF DNMT 
2.1. Classification 
  To date, multiple DNMTs appear to be present in human, 
with varying degrees of specificity toward unmethylated and 
methylated DNA substrates, including DNMT1 (gene ali-
ases:  CXXC9, DNMT,  FLJ16293,  MCMT,  MGC104992) 
[23], DNMT2 (gene aliases: RP11-406H21.1,  TRDMT1, 
M.HsaIIP,  PuMet, RNMT1) [24], DNMT3A (gene aliases: 
DNMT3A2,  M.HsaIIIA), DNMT3B (gene aliases: ICF, 
M.HsaIIIB) [25] and DNMT3L [26]. 
2.2. Structure 
  Structurally, all DNMTs share a common catalytic do-
main in the carboxyl terminus, which consists of several -
helical and -sheet structures. This catalytic domain is char-
acterized by the presence of six conserved amino acid mo-
tifs, namely I, IV, VI, VIII, IX and X. Motif I and X are filed 
together to form the most of the binding site for methyl do-
nor (S-adenosyl-L-methionine, SAM). Motif IV contains the 
prolylcysteinyl dipeptide that provides the thiolate at the 
active site. Motif VI contains the glutamyl residue that pro-
tonates the 3 position of target cytosine. Motif IX has a role 
in maintaining the structure of the target recognition domain, 
usually located between motif VIII and IX [27,18]. The N-
terminal domains of DNMT3A and -3B exhibit some ho-
mology, but they differ significantly with N-terminal do-
mains of DNMT1 [28]. The N-terminal regulatory and the C-
terminal catalytic domains were linked by a short fragment 
of repeated GK dipeptides. DNMT3L was assigned to the 
DNMT3 family on the basis of the high conservation of its 
N-terminal PHD-like zinc finger domain with the corre-
sponding domains of DNMT3A and -3B. The C-terminus of 
DNMT3L also show partial homology to the C-terminal 
catalytic regions of DNMT3A and -3B, although key cata-
lytic residues involved in the transfer of the methyl groups 
are not conserved in DNMT3L [29,30]. The unique terminal 
domains of mammalian DNMTs harbor several regulatory 
domains that mediate both protein-protein and protein-DNA 















Fig. (2). Structural and the functional domain of DNMTs. PDB: proliferating cell nuclear antigen (PCNA) binding domain; NLS: nuclear 
localization signal sequence, is responsible for localization of DNMTs in the nucleus; ATRX: cysteine alpha thalassemia retardation on the X 
rich zinc finger DNA binding motif; PHD: polybromo homology domain, targeting DNMTs to the replication foci; GK: GK-rich repeats; 
MTase: methyltransferase; PWWP tetrapeptide is only present in N-terminal domains of DNMT3A and DNMT3B; The C-terminal domain 
contains six conservative motifs I, IV, VI, VIII, IX and X. Mapped interactions with DNMT3A, DNMT3B, PCNA, histone deacetylase 
(HDAC)1 and -2 are shown above the diagram. 338    Current Genomics, 2009, Vol. 10, No. 5  Tang et al. 
2.3. Biological Functions 
2.3.1. DNMT1 Family 
  Functionally, DNMT1, the 1st identified DNMT, is the 
primary enzyme responsible for copping methylation pat-
terns after DNA replication because it localizes to replication 
loci and it has a 7- to 21- fold preference for hemi-
methylated DNA substrates than unmethylated DNA sub-
strates, thus this protein is referred to as a maintenance 
methyltransferase (i.e., copies the methylation patterns of the 
parental strand to the daughter strand during DNA duplica-
tion) [31,32]. Interestingly, recent studies have associated 
DNMT1 with methylation of unmethylated human CpG is-
lands in cancer cells. They reported that a majority of the de 
novo methyltransferase activity was provided by DNMT1 
with gene-specific preference, charging the previous knowl-
edge of DNMT1. Then they substantiated the specificity of 
DNMT1 was not inherent to the enzyme but may be due to 
associated cellular factors [33]. And the finding that 
DNMT1-mediated suppression of the unmethylated rDNA 
promoter involves de novo methylation of the promoter 
could further substantiate the de novo methylation activities 
of DNMT1 [34]. Many researchers hold that DNMT1 activ-
ity is required for de novo methylation at non- CpG cytosi-
nes, and perhaps to an extent even in CpG islands [35,33]. In 
addition to methyltransferase activity, interaction with 
DNMT1-associated protein (DMAP), E2F1, HDAC and 
methyl-CpG binding proteins (MBD) make DNMT1 a cru-
cial element of transcription suppression complex [36,37].  
2.3.2. DNMT2 Family 
  A summary to the previous observations on DNMT2 
family, DNMT2 does not methylate DNA but instead methy-
lates small RNA. Mass spectrometry showed that this RNA 
is aspartic acid transfer RNA (tRNA (Asp); TRD) and that 
DNMT2 specifically methylates cytosine-38 in the anticodon 
loop, and the function of DNMT2 was highly conserved 
[38,39]. Importantly, Hermann et al. provided compelling 
evidence that DNMT2 has some de novo CpG methylating 
capacity [40].  
2.3.3. DNMT3 Family 
  DNMT3A and -3B are essential for early embryonic de-
velopment and the establishment of repressive complex. Be-
cause DNMT3A and -3B have similar affinities for both un-
methylated and hemi-methylated DNA substrates, their func-
tion as the only bona fide de novo DNMT (i.e. to form spe-
cific methylation patterns in the unmethylated strand without 
any models) to affect the methylation status of normally un-
methylated CpG sites and to recruit HDAC to chromatin 
[41]. However, there were studies showing both DNMT1 
and DNMT3 exhibit some levels of both maintenance and de 
novo methylation activity in vitro, suggesting that this classi-
fication of the DNMT may be over simplified [26]. Recently, 
studies by Geiman and coworkers found a role for DNMT3B 
in maintaining genomic stability independent of its enzy-
matic activity. This could potentially be explained by the 
participation of DNMT3B in the condensation complex, 
which is involved in proper segregation of sister chromatids 
during mitosis [42]. DNMT3A2, a shorter isoform of 
DNMT3A, is also required for genomic imprinting [43]. 
DNMT3A2 and DNMT3B, along with the four core his-
tones, were identified as the main in vivo interaction partners 
of epitone-tagged DNMT3L [44]. 
  DNMT3L, a DNMT3A and -3B like protein, is inactive 
on its own, but DNMT3L plays a key role in allowing DNA 
methylation during the maturation of germ cells. In theory, 
DNMT3L could ‘regulate’ other active DNA methyltrans-
ferases or could target DNA methylation to certain areas, 
such as imprinting centers [45,46]. Some data suggest that 
DNMT3L may be a probe of histone H3 lysine 4 (H3K4) 
methylation, and if the methylation is absent, then DNMT3L 
could induce de novo DNA methyalion by docking activated 
DNMT3A2 to the nucleosome, which indicates that 
DNMT3L might function together with these two de novo 
DNA methyltransferases [44,47]. DNMT3L is the first 
stimulatory factor for DNA methylation to be described. 
Dnmt3L is controlled via  its promoter methylation during 
embryonic development. Genetic studies showed that 
DNMT3A, -3B and -3L are all involved in the methylation 
of the Dnmt3L promoter. Interestingly, DNMT3L also con-
tributes to the methylation of its own promoter in embryonic 
development. We therefore can propose an auto-regulatory 
mechanism for the control of DNA methylation activity 
whereby the activity of the Dnmt3L promoter is epigeneti-
cally modulated by the methylation machinery including 
DNMT3L itself (Fig. 3A) [29].  
 In  vitro methylation assays have shown that DNMT3 
family could cooperate with DNMT1 to extend methylation, 
and DNMT1, DNMT3 could bind HDAC and medicate for-
mation of repression complex surrounding the certain pro-
moter region, because of the HDAC binding motif in their 
structures (Fig. 2). Mostly, it’s acknowledged that the nor-
mal methylation patterns was established by DNMT1 coop-
erated with DNMT3 family, the maintenance function of 
DNMT1 methylation guarantees the initiation of DNMT3 de 
novo methylation, the DNMT3 elevates the methylation level 
to the wanted level [27,32]. In a word, DNMTs play an es-
sential role in epigenetics, which control the DNA methyla-
tion status at level.  
  Since the diverse roles, functions, activities of DNMTs 
have being reported, it’s therefore reasonable to speculate 
that the de novo or maintenance function is cell lines, gene 
sequence and cellular setting specifically, thus when the ex-
perimental conditions come to different material, different 
target, the diverse results may be emerging.  
3. DISREGULATED DNMT CORRELATED WITH 
LUNG TUMORIGENESIS 
3.1. Lung Tumorigenesis Induced by Disrupting Cell Cy-
cle and its Inner Balance 
  DNMT1 and DNMT3B, localized in the nucleolus, could 
synergistically maintain the methylation profile of the human 
rDNA promoter and regulate its expression. However 
DNMT3B represses the rDNA promoter activity by a methy-
lation independent mechanism, which is different from that 
of DNMT1. Thus the DNMTs could regulate the rRNA 
level, ribosomes synthesis and cell cycle. This is consistent 
with the finding that reduced methylation of the rDNA pro-












Fig. (3). Models of DNMT associated methylation and gene silence.  
(A) Auto-regulation of DNMTs. DNMT1, DNMT3s all could methylate (Met) the Dnmt3L gene, thus the DNMT3L expression (Exp) is re-
pressed. On the other hand, the DNMT3L could stimulate (Sti) the methyltransferase activity of DNMT1, DNMT3A and -3B.  
(B) Mechanism that DNMT caused gene methylation. First, certain adaptors (HP1, lymphoid-specific helicase (LSH)) recognize the specific 
gene site, and serve as a scaffold protein to recruit DNMT3B. Second, the DNMT1 makes an interaction with DNMT3A and HDACs, they 
then form the repression complex via the DNMT3B, and HDACs remove the acetyl from the histone tails. Finally, the DNMTs behave their 
methyltransferase activity, making the gene methylated.  
(C) DNMT3A and -3B are the de novo methyltransferase, the DNMT1 maintains the methylation status, while the methylated genes are often 
silenced. This methylation process could be reversed by some demethylation substrates. 
control tissues [34]. On the other hand, the over-expression 
of DNMTs can lead to ribosomal DNA (rDNA) hypermethy-
lation, subsequently affect the methylation of ribosomal 
RNA (rRNA) at 2’-O position. A pre-rRNA must undergo 
maturation to form a functional rRNA, and the pre-rRNA 
would be degraded during this process if the 2’-O position is 
non-methylated. If so, the functional ribosome can’t be bio-
synthesized, and the cell-cycle would become arrested once 
without the functional ribosome, therefore the DNMT statis-
tically affects cell proliferation, i.e. the higher DNMT activ-
ity, the higher speed of cell proliferation [48]. In another 
study, when the level of DNMT1, DNMT3A and -3B in lung 
cancer cell lines were normalized against PCNA, no over-
expression of DNMTs were observed, suggesting over-
expression of some of these genes may be a reflection of 
increased cell proliferation [49]. To our knowledge, 
DNMT1, not only affects cell cycle, but is also regulated by 
cell cycle via the pRB/E2F pathway. More recently, a study 
investigated cell cycle-specific gene expression indentified 
DNMT1 as part of a G1-S cycle cluster [50]. Kishikawa et 
al. through investigating the expression of Dnmt1, and found 
that the control elements (e.g. SP1, SP3, P300) of Dnmt1 
were mainly recruited at G1, S phase respectively, which 
coordinately regulated the expression of Dnmt1 at S phase. 
These data suggested that Dnmt1 was regulated in cell-cycle 
dependent manner [51]. Thus, there are considerable evi-
dences to support the cell cycle-specific regulation of 
DNMT1 [52]. Although some results conflicted with the 
view that cell proliferation was inversely associated with 
differentiation [53], most studies available so far were con-
sist with this conclusion. Hence, DNMT over-expression not 
only blocks normal differentiation progress but also assists 
proliferation. Since there is a homeostatic balance, i.e. pro-
liferation and differentiation in each cell, once this balance is 
disrupted, the cell growth becomes out of control, which lead 
to tumor formation. During tumorigenesis, when cells ex-
press a specific protein, which can interact with DNMT and 
stabilize it. From then on, the cell is able to secrete self-
stimulus and becomes exo-stimulus independent, cell differ-
entiation is further repressed. 
3.2. Lung Tumorigenesis Induced by Silencing TSGs 
  Although it is well established that the predominant con-
sequence of methylation is gene silence, it is less clear if this 
is mediated directly or indirectly [54,55]. The direct inhibi-
tion involves interactions of methylated DNA with methyla-
tion-sensitive factors (E2F, CREB, AP2, cMyc/Myn, NF-kB, 
cMyb, ETs), disabling their DNA-binding ability, and re-
pression of transcription [54,55]. In addition, methylated 
DNA recruits m
5CpG-binding proteins (MeCP) and m
5CpG-
binding domain proteins (MBD). MeCP1 and -2 bind spe-
cifically to methylated DNA in whole genome, and form 
spatial obstacles that are unable to bind transcription factors 
(TFs) to promoter sequences. MBD protein family, including 
MBD1, MBD2, MBD3, MBD4, and uncharacterized Kaiso 
complex, binds to methylated DNA [56,57]. While an indi-
rect repression may be involved in MBD containing proteins, 
the MBD-CpG complex recruiting HDAC, resulting in a 
deacetlyated repressive chromatin structure [58,59]. Recent 
findings suggest that a full picture was much more complex, 
with cancer-specific DNA hypermethylation (associated with 
histone modification) affecting whole gene ‘neighborhoods’ 
up to an entire chromosome band [60]. More recently, as a 
result of aberrant histone methylation without DNA methyla-
tion, a novel mechanism of cancer-specific loss of expres-
sion of neighboring genes has been reported [61].  
  It is only now that the nature of DNA hypermethylation 
induced gene silencing start to be understood, which is me-
diated by a series of events that include methylation of cyto-340    Current Genomics, 2009, Vol. 10, No. 5  Tang et al. 
sines within the gene promoter and the establishment of het-
erochromatin in which the histone tails are modified through 
effects on acelylation, phosphorylation, methylation and 
ubiquitylation [62]. There is an agreement on the universal 
coexistence of both histone modification and DNA methyla-
tion at silenced gene and Cross-talk between these epigenetic 
mechanisms during gene silencing [63,64]. However, there is 
no concensus on which epigenetic mechanism initiates and 
steers this communication. In one scenario, DNA methyla-
tion may be the primary marker for gene silencing that trig-
gers events leading to non-permissive chromatin state [65]. 
The process involved through the MePC2, HDAC were re-
cruited to the methylated DNA, resulting in a deacetylated 
repressive chromatin structure [58]. In another scenario, CpG 
methylation was not a primary cause of initiation of tran-
scription inactivation, but maintained long-term silencing of 
genes that have already been switch off by other mechanisms 
[66-69]. From the subtle relationship between DNA methyla-
tion and histone modification, some studies indicated that 
firstly, the epigenetic information could flow from histone to 
DNA through histone deacetylation and DNA methylation 
[70]. DNA methylation might exert a positive feedback to 
histone modification, so the epigenetic information could 
come back to histone [71]. To explain the mechanism of 
DNA methylation coordinated histone modification in gene 
silencing, it has been proposed a self-reinforcing epigenetic 
cycle model that maintains and perpetuates a repressed 
chromatin state: Firstly, methylated histone tails interact with 
adaptor protein HP1, LSH, leading to DNMT3B recruiting. 
Secondly, through the directly binding of LSH with 
DNMT3B, HDAC and DNMT1 are recruited to the site, and 
forming the large protein complex. Thirdly, the recruited 
HDAC deacetylate histone tails, initiating the transitional 
transcriptional repression. Then, the more DNMTs recruited, 
the higher concentration of DNMTs, and cause the specific 
methylation to keep the gene silence. Eventually, MBD-
containing proteins bind to methyl-CpG site (mCpG), and 
mCpG-MBD complexes interact with HP1, recruiting his-
tone-lysine methyltransferase (HKMT), re-methylating the 
histone [72]. This model has indicated that DNA methyla-
tion, histone deacetylation and histone methylation work in a 
cooperative manner to enhance and maintain the epigenetic 
regulation, keeping the target gene in a semi-permanent si-
lence state (Fig. 3B, C). Other than the methylation mediated 
gene silence, the relatively large N-terminal domains of 
DNMTs can also mediate transcriptional repression of genes 
independent of their methyltransferase activity [73,36,37]. 
  In lung cancer, several sets of genes including the tumor 
suppressor gene (TSG) have been shown to be frequently 
methylated and inactivated (Table 1).  
3.3. Lung Tumorigenesis Induced by Causing Epigenetic 
and Genetic Changes 
  In fact, DNA methylation is a more stable epigenetic 
modification compared with other epigenetic patterns. In 
successive generations of an Arabidopsis mutant lacking the 
maintenance of methylation at CpG dinucleotides (mCpG), 
Mathieu et al. found that the loss of mCpG triggers genome-
wide activation of alternative epigenetic mechanisms. These 
compensatory responses act in a stochastic fashion and lead 
to the accumulation of aberrant epigenetic patterns. Latterly, 
Karpf and colleagues investigated the potential link between 
DNA hypomethylation and/or DNMT loss and genomic in-
stability in human cancer cells, and presented a number of 
novel findings, one of which showed that DNMT loss re-
sulted in bona fide chromosomal instability [97]. These re-
sults suggest that mCpG might provide not only direct epi-
genetic regulation but also coordinate and stabilize epige-
netic memory required for faithful replication [98]. Tran-
scriptional silencing by CpG island hypermethylation rivals 
genetic changes as a critical trigger for neoplastic develop-
ment and progression [99]. DNMT induced epigenetic altera-
tions may arise in any stage of tumor development, but re-
cent studies have established that these alterations occur 
mostly in the precancerous stage. Early epigenetic changes 
might then lead to the genetic alterations, and all these 
changes could drive cancer formation [100]. For example, 
the aberrant DNA methylation, silencing the O-6-
methylguanine-DNA-methyltransfease (MGMT) gene, left 
the cell unable to directly remove adducts from the O posi-
tion of guanine, and further contributes to genetic alterations. 
Furthermore, DNMT can assist methylated cytosine deami-
nation (i.e., cause the C to G transition mutation). When 
DNA duplicated, this mutation induced a G: C to A: T muta-
tion, which could cause genetic alterations [101]. Conse-
quently, both epigenetic alterations and genetic changes are 
important throughout cancer development. At the initial 
stages of tumorigenesis, epigenetic alterations enable the 
cells to form tumor-like clones and induce genetic altera-
tions. Subsequent tumor development and metastasis pro-
gress are not only dependent on genetic mutation but also the 
accumulation of epigenetic alterations. In lung cancer, one of 
the most consistent genetic abnormalities is the loss of the 
short arm of chromosome 3, the hyperproliferation of chro-
mosome 1 and 12. The loss of 3p alleles was observed in 
>90% of SCLC and approximately 50% of NSCLC. Some 
tumor suppressor genes such as RASSF1A, on 3p21, are ab-
sent in all SCLC and in 65% of NSCLC. Other candidates at 
the 3p are FHIT [102], beta-catenin [103], RARB [83], CAV1 
(caveolin-1) [104]. Hence, tumorigenesis is the outcome of 
epigenetic alterations in cooperation with genetic alterations. 
3.4. Which DNMT is Dominant for Inducing Lung Tu-
morigenesis 
  The over-expression of DNMT1 is an early indicator in 
the development of lung cancer, which occurs earlier than 
the methylation disturbance. This conclusion was first im-
plied in studies where only a 2-fold over-expression of the 
DNMT1 gene in NIH3T cells resulted in a marked increase 
in overall DNA methylation and tumorigenic transformation 
[105]. There are also reports that the high DNMT1 activity 
would promote tumor cell proliferation. The RNA interfer-
ence-based knockdown experiment in NSCLC cell line A549 
has provided evidence that DNMT1 level correlates with the 
A549 proliferation ability and clone forming ability. The 
exact mechanism is still poorly known, which is maybe re-
lated to P21 expression [106]. The hypermethylation of TSG 
is a common thing in lung cancer, and it is generally ac-
knowledged that DNMT1 is correlated with hypermethyla-
tion in the TSG promoters, especially among smoking SCC 
patients. Suzuki et al. employed siRNA to down-regulate the 
DNMT1 expression in NSCLC cell line NCIH1299, and Potential of DNMT and its Epigenetic Regulation  Current Genomics, 2009, Vol. 10, No. 5    341 
Table 1.  TSGs that are Commonly Methylated in Lung Cancer 
TSGs Function  References 
BRACA1  DNA damage repair  [74] 
BVES   Cell shape and movement  [75] 
Caspase-8  Apoptosis [76] 
CDH1(E-cadhein)  Cell-cell adhesion  [77,75,78] 
CDH13(H-cadhein)  Cell adhesion  [79,80] 
CDKN2A(p14)  cyclin-dependent kinase inhibitor  [63] 
DAPK1  Interferon-induced apoptosis  [75] 
Estrogen receptor  Growth control  [81] 
FHIT  Cell apoptosis  [82] 
hsRBC  DNA repair  [83] 
ING1   Cell growth and apoptosis  [84] 
KCNH5  Membrane voltage gate  [75] 
KISS1  Chemotaxis and invasion  [85] 
MGMT  DNA repair  [75] 
MTHFR  DNA synthesis and repair  [63] 
MYO18B  Growth control  [86] 
P16  Cell cycle regulation  [79] 
P15/INK4b  Cell-cycle control  [87] 
P53  Cell cycle and differentiation  [88] 
PTEN  Cell movement and adhesion  [89] 
RARB Signal  transduction  [75] 
RASSF1A  Cell cycle arrest  [63,75] 
RB  Cell-cycle control  [90] 
RUNX  Transcription factor  [91] 
SOCS-3  Growth control  [92] 
SOCS-7  Growth control  [93] 
STK11   Signal transduction  [94] 
WWOX  Transcription regulation, protein degradation  [82] 
TMS1  Apoptosis [95] 
T(brachyury homologue)  Transcription regulation  [96] 
 
resulted in >80% reduction of promoter methylation in 
RASSF1A, CDKN2A (alias P16/INK4a), CDH1 and HPP1 
gene. They also observed that the reactivation of methyla-
tion-silenced gene after treatment [78]. However, some ex-
periments showed that simply down regulated DNMT1 ex-
pression was unable to reverse the DNA methylation and 
reactivate the TSG [107]. In addition, a poor prognostic 
trend was found for patients with highly expressed DNMT1 
protein and the association was apparent in SCC patients 
[65]. Similar results were obtained by using Cox propor-
tional hazards regression analysis to determine whether ele-
vated mRNA levels of Dnmt were an independent prognostic 
factor, and it is found that deregulation of DNMT1 was an 
independent prognostic factor in NSCLC, and the elevated 
DNMT3B did not affect patient prognosis [108].  
  It is also commonly acknowledged that DNMT3B corre-
lated with TSG hypermethylation in lung cancer. But many 
conflicting results have emerged [107]. The elevated mRNA 
levels of Dnmt3b were not significantly associated with hy-
permethylation of the six TSGs (p16, RAR2, H-Cadherin, 
GSTP1, RIZ and FHIT), thereby suggesting that other factors 
might be involved in CpG island hypermethylation of TSG 
in a gene-specific basis in primary NSCLC [108]. While 
another study showed that Dnmt3b knockdown could arrest 342    Current Genomics, 2009, Vol. 10, No. 5  Tang et al. 
lung cancer cell growth, assist apoptosis and re-activate the 
TSG, which has been silenced due to hypermethylation 
[101]. This study also claimed DNMT3B was essential for 
lung tumorigenesis and progression.  
  DNMTs should interact with other active factors to per-
form their biological functions in vivo. An interaction be-
tween members of DNMTs family has been well established, 
in which is normally in a cooperative manner, DNMT1 is 
dominant, while DNMT3B assists and cooperates with 
DNMT1 to pay its role in lung tumorigenesis [65]. 
3.5. The Chief Culprit, Smoke, Induces Lung Tumori-
genesis Mainly Through DNMT 
  In addition to chronic inflammation and/or persistent 
infection with pathogenic microorganisms, cigarette smoking 
is another major factor associated with alternations of DNA 
methylation during multistage lung tumorigenesis [109,18]. 
Several animal models and human NSCLC samples show 
that cigarette smoke leads to high level DNMT activity 
[110,111]. In contrast, AC is often, especially in women, not 
associated with cigarette smoke, and promoter hypermethy-
lation of the MGMT gene is more common in AC in non-
smokers than smokers, furthermore, epidemiologic data also 
suggest that male and female patients might have different 
susceptibilities to tobacco carcinogens [112,113]. To eluci-
date the phenomenon that DNMT was highly over expressed 
in smokers with lung cancer, some reports have shown that 
tobacco components stimulated Ap1, Akt and NFkB–
dependent signaling pathway in lung cells, and the Ras-Ap1 
signaling pathway could enhance the DNMT expression 
[114-116]. Exposure to tobacco smoke may induce selective 
changes in a limited set of key regulatory transcription fac-
tors, including SP1 protein, the Cis-acting factor that nor-
mally protects the islands from methylation [117]. The over 
expression of DNMT leads to the promoter and 5’ flanking 
regulation region methylation of MGMT gene, which down-
regulates the expression of MGMT protein, a direct DNA 
repair enzyme that protects cells from the carcinogenic effect 
of alkylating agents in cigarettes, by removing adducts from 
the O6 position of guanine [118]. If MGMT is hypoexpres-
sive or inactivated, DNA lesion could not be corrected, the 
G:C to A:T mutation will form, which contributes to the 
formation of lung cancer. Many experiments have confirmed 
that lung tumorigenesis was significantly correlated with the 
activity of MGMT [119]. In light of the mechanism that 
smokes cause lung cancer, Lemjabbar and colleagues have 
demonstrated that tobacco smoking could activate the Wnt, 
Hh pathway, which play an essential role in lung tumori-
genesis [120]. Other studies have shown that tobacco smoke 
causes genetic alterations such as the loss of chromosome 3, 
where is loci of abundant TSGs [121]. 
4. NOVEL LUNG CANCER DIGNOSIS STRATEGY 
BY METHYLATION PROFILES 
  It was well demonstrated that DNA methylation patterns 
play a key role in lung tumorigenesis [16,110]. Distinct 
methylation patterns have provided molecular distinctions 
between different histological subtypes of lung cancer. (i.e., 
cancers from different organs display distinct methylation 
profiles), even different histological subtypes of cancers 
within a given organ have appeared to have distinct methyla-
tion profiles. DNA methylation profiles of both normal and 
cancer tissues tend to be organ-specific, and hot spots of 
DNA hypermethylation may reflect the diversity of carcino-
genetic factors. This has been illustrated by the recent analy-
sis of DNA methylation levels in 91 lung cancer cell lines: 7 
out of the 23 CpG island loci tested showed a significant 
difference in the methylation values between SCLC and 
NSCLC cell lines [122]. This was further supported by the 
results of Tsou and colleagues, who examined the DNA 
methylation status of the 14 loci in 6 malignant mesothe-
lioma (MM) tissue samples, 7 AC tissue samples, 11 non-
tumor lung tissue samples, 8 AC cell lines and 10 MM cell 
lines and gave a similar outcome [123]. When using DNA 
methylation profiles as indicators to estimate carcinogenetic 
risk, elimination of such etiological factors may be efficient 
for cancer prevention. Consequently, early diagnosis of can-
cers using DNA methylation profiles as indicators may be a 
promising avenue. Recently developed technologies for ac-
cessing genome wide DNA methylation status will be useful 
to identify the DNA methylation profile, which is the opti-
mum indicator of prognosis. The distinct profile therefore 
may serve as a novel strategy for lung cancer diagnoses and 
therapy.  
  Multiple genes often intensively methylated in SCLC are 
RASSF1A [78], hsRBC [83], CAV1 [104] and RARB [124]. In 
contrast, the frequencies of methylation of MGMT [112], 
PAX5-alpha, PAX5-beta [125], TSLC1 [126], hMLH1, 
hMLH2 [127], DAPK [128], P14IRF [129], FHIT [130], 
beta-Catenin [80] are remarkably higher in NSCLC than 
SCLC. The P16 gene is more frequently methylated in SCC 
than AC, but the APC [123], CDH13 [131] are seemly re-
versed. Others liable to methylation in lung cancer are shown 
in Table 1.  
5. DNMT RELATED EPIGENETIC CANCER THER-
APY 
5.1. Overview 
  Despite of new drugs and therapeutic regiments, the 
prognosis for lung cancer patients has not significantly 
changed in the last 20 years. Surgery remains the main ther-
apy for patients, but large fraction of patients cannot undergo 
curative resection. Innovative therapeutic strategies are ur-
gently needed for lung cancer treatment. Because of the re-
versibility of epigenetic events, the pharmacological agents 
that can reverse this epigenetically mediated progress make 
it an ideal target for prevention and therapy [132,133]. Epi-
gentically active drugs currently within clinical trials include 
histone deacetylase inhibitors (HDACi) and DNMT inhibi-
tors (DNMTi) [134], and the most extensively studied are 
DNMTi [135]. Considerable promise lies in the further de-
velopment of DNMT targeting therapies that already have 
shown antitumorigenic effects for lung cancer and several 
malignancies [136,137] Table 2. 
5.2. Nucleoside DNMTi 
  Among the sea of DNA demethylating agents, the most 
widely used in experimental and clinical scenarios is the 
nucleoside DNMTi, which mainly comprise cytosine analogs Potential of DNMT and its Epigenetic Regulation  Current Genomics, 2009, Vol. 10, No. 5    343 
Table 2.  The Studies of DNMTi for Lung Cancer Therapy 
Drug Phase  Cancer  Results  References 
5-Aza-CR  Approved 
by FDA 
Mainly for MDS  improve overall response rates, time to 
leukemic progression, and quality of life 
[182] 
5-Aza-CdR  Approved 
by FDA 
Mainly for MDS  More effective than 5-Aza-CR  [http://www.fda.gov/CDER/Offices/
OODP/whatsnew/decitabine.htm] 
5-Aza-CR I/II Recurrent  NSCLC  On-going  [http://clinicaltrials.gov/ct2/show/NC
T00387465] 
5-Aza-CdR I  Metastatic  NSCLC  5-aza-CdR in combination with valproic aci is 
well tolerated and shows promise in gene 
demethylation 
[172] 




show promising efficacy in combination with 
the Valproic acid 
[183] 
Fazarabine II  Advanced  NSCLC  has no demonstrable activity in metastic 
NSCLC patients 
[184] 
Zebularine Preclinical  AML  inhibits cell proliferation, arrests cells at G2/M, 
and induces apoptosis 
[185] 





Preclinical  Lung cancer  Reduce incidence of lung cancer  [91] 
Hydralazine II  Lung cancer and other 
solid tumor 
Decrease the methylation and reduce the 
chemoresistance of lung cancer and other 
refractory solid tumor 
[162] 
MG98 I  Lung cancer and other 
advanced solid 
malignancies 
Suppression of DNMT1 expression  [187] 
MiRNA-29 Preclinical  Lung  cancer  Restored silenced TSGs in A549 and H1299 
lung cell lines 
[167] 
DNMT1-siRNA Preclinical  Lung  cancer  suppression of cell proliferation and clone-
forming ability 
[106] 
MMA  Preclinical  Lung cancer  Inhibit invasion and metastasis  [174] 
 
and cytidine deaminase analogs, including 5-Aza-cytidine 
(5-Aza-CR, azcitidine, Vidaza), 5-Aza-2’-deoxycytidine (5-
Aza-CdR, decitabine, Dacogen), 1--D-arabinofuranosil-5-
azacytosine (fazarabine) and 1--D-ribofuranosyl-2 (1H)-
pyrimidinone (zebularine) [4, 138-140]. The archetypal 
DNMTi 5-Aza-CR is a simple derivative of the nucleoside 
cytidine, and its demethylating activity has been reported 30 
years ago [141]. Today, 5-Aza-CR has been approved by the 
Food and Drug Administration (FDA) as an antitumor agent 
for the treatment of myelodysplastic syndrome (MDS) [135]. 
And in prostate cancer cell lines PC3, Dul45 and LNCap, 
growth arrest and DNA damage inducible, alpha 
(GADD45) was upregulated by the treatment of DNMTi 
(5-Aza-CR) and confer sensitivity to chemotherapy, which 
represent a potential way for treatment of prostate cancer 
[142]. Schmitz further reveal that the GADD45protein also 
bare demethylating ability, when it target to the DNA, 
GADD45 triggers demethylation of the promoter proximal 
DNA by recruiting the nucleotide excision repair (NER) ma-
chinery to remove methylated cytosines [143]. 5-Aza-CR is 
phosphorylated to 5-Aza-CR diphosphate which can be re-
duced to 5-Aza-CdR diphosphate and subsequently incorpo-
rated into DNA. 5-Aza-CdR is phophorylated to 5-Aza-CdR 
mono- and diphosphate, and then incorporated into DNA. 5-
Aza-CdR nucleotide of DNA forms a covalent bond with the 
DNMT and inactivates these enzymes [144,145]. It has sin-
gle-agent activity in myeloid malignancies, including mye-
losplasitc syndrome, acute myelogenous leukemia, and 
chronic myelogenous leukemia [146,135]. There were also 
reported that 5-Aza-CdR can selective degrade DNMT1 by a 
proteasome pathway in certain settings [147]. Zebularine, 
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deoxyZebularine 3-phosphate and then is incorporated into 
DNA. 2’-deoxyZebularine nucleotide of DNA irreversibly 
inactivates DNMTs by covalently binding to these enzymes 
[148,149]. Its demethylating and antitumor activity was re-
ported later [148], but its oral bioavailability was low [150]. 
The drug also been reported preferentially depleted DNMT1, 
and with some specificity toward cancer cells [149]. Latterly, 
in order to study 5-Aza-derivatives of cytosine, Byun et al. 
synthesized a intermediate product, 2`-deoxy-N4 [2-(4-
nitrophenyl)ethoxycarbonyl]-5-azacytidine (N4-NPEOC-5-
CdR), and found that such intermediate product can be acti-
vated to 5-Aza-CdR and decrease global and specific DNA 
methylation like other cytosine analogs in the cells express-
ing carboxylesterase 1 [151]. The other pyrimidine analogs, 
5-fluorocytidine is also a mechanic inhibitor of DNMT, and 
currently under clinical development [151], but treatment 
cells with 5-fluorocytidine do not induce the degradation of 
DNMT1 [147].  
  One difficulty in using demethylating agents like 5-Aza-
CR in vivo is the ability to achieve pharmacologically active 
does without systematic toxicity. The results from in vivo 
studies carried out by Baylin were the first to demonstrate 
that HDACi sodium phenylbutyrate can synergize with de-
methylating agent 5-Aza-CR to prevent lung tumor devel-
opment. In that setting, low-dose demehylating agents com-
bine with HDACi achieve pharmacologically active does 
without systemic toxicity [110]. The observations that inten-
sification of the 5-Aza-CdR dose markedly increased its an-
tineoplastic acitivity in mouse models of cancer have provide 
a strong rationale to perform clinical trails using dose inten-
sification of 5-Aza-CdR to maximize the chemotherapeutic 
potential of this epigenetic agent in patient with cancer 
[152]. Contrarily, there were also reported that lower doses 
of 5-Aza-CdR were more effective at inhibiting DNMT in 
vitro and in vivo [153,154]. When come to clinical trail, it’s 
important to optimize the dose-schedule of demethylating 
agents. 
  Although the wildly and extensively use of nucleoside 
DNMTi, but these agents, like current cytotoxic chemother-
apy, cause myelosuppression among other side effects that 
limit exploitation of their demethylating properties, so the 
development of alternative DNMTi is urgent needed [155]. 
5.3. Dietary DNMTi 
  During the past years, we have made tremendous pro-
gress in understanding of dietary components that prevent or 
reverse the DNMT induced TSGs inactivation.  
  It is well known that catechol-o-methyltransferase 
(COMT) –mediated rapid methylation would not only sig-
nificantly drain the intracellular pools of SAM, but it would 
also form equimolal amounts of S-adenosyl-L-homocysteine 
(SAH), which is the demethylated SAM and is a feedback 
inhibitor of various SAM-dependent methylation processes 
(DNMT-mediated methylation). Relying on the knowledge 
of that various catechol-containing dietary polyphenols are 
excellent substrates for the COMT-mediated methylation, 
Lee and colleagues provide a general mechanistic basis   
for the notion that a variety of dietary catechols (caffeic   
acid, catechin, epicatechin, (-)-epigallocatechin-3-o-gallate 
(EGCG), guercetin, fisetin, myricetin and chlorogenic acid) 
can function as inhibitors of DNA methylation in a complex 
way. Some catechol-containing dietary polyphenols (such as 
catechin and epicatechin) have two mechanistic components 
involved in the inhibition of DNA methylation: One is the 
directly inhibition of the DNMT (independent of COMT-
mediated methylation), and the other is the indirectly inhibi-
tion of the DNMT through an increase in SAH formation 
during the COMT-mediated O-methylation of these dietary 
chemicals. EGCG, the main polyphenol compound in green 
tea, whose inhibitive activity is mainly owed to the direct 
inhibition of the DNMT, is a more potent and efficacious 
inhibitor of DNMT than other dietary catchols in vitro, but 
under in vivo experimental conditions, the former behaves 
less activity than the latter, because EGCG is an inferior sub-
strate for COMT and has a relatively lower intercellular 
bioavailability than the latter (Fig. 4) [156,157]. Reactivation 
of some methylation-silenced genes (INK4, RAR, 
MGMT, hMLH1) by EGCG was also demonstrated in hu-
man cancer cells (colon cancer cell, esophageal cancer cell, 
prostate cancer cell) [158]. 
  Apple, tea and their products are commonly consumed, 
which are a rich source of phenolic constituents. Apple 
products have widely reported to post-translational inhibit 
the expressing of DNMT1 and DNMT3b [159,160]. Latterly, 
genistein from soybean has been demonstrated to inhibit 
DNMT in vitro, and Fang M et al. associated this with the 
reactivation of P16
INK4a [161].  
  Considering that some aberrant DNA methylation is pre-
sent in early stages of carcinogenesis, there is a possibility 
that such dietary DNMTi may be useful for cancer preven-
tion and may less effective in therapy. Further studies about 
the novel DNMTi have been carried out [144]. 
5.4. Others 
  There are also many less well characterized classes of 
DNMTi under development, such as hydralazine, RG108, 
Non-coding RNA (ncRNA), procaine, procainamide and 







Fig. (4). DNA methylation and its modulation by the COMT-mediated methylated catechols. Both methylation reactions use the same 
pools of methyl donor SAM, and both contribute to the formation of SAH as a feedback inhibitor. Potential of DNMT and its Epigenetic Regulation  Current Genomics, 2009, Vol. 10, No. 5    345 
derway for development, the cardiovascular drug hydralazine 
has been found with demethylating property through the 
linkage with immunologic reaction inducing effect and the 
participation of DNA methylation disorders in immune dis-
eases.  
  The clinical safety and tolerability have been demon-
strated by decades of extensive hydralazine use for hyperten-
sive disorders. For the moment, hydralazine is being evalu-
ated, along with histone deacetylase inhibitors either alone or 
as adjuncts to chemotherapy and radiation for lung cancer 
and other refractory solid tumors [155,162]. From the phase 
II, single-arm study of hydralazine and magnesium val-
provate added to the same schedule of chemotherapy on 
which patients were progressing, Candelaria et al. found that 
demethylating agent hydralazine combined with HDACi 
magnesium not only reduced global DNA methylation, his-
tone deacetylase activity, and promoter methylation, but also 
reduced the chemoresistance of the refractory solid tumors 
[162]. 
  RG108, a novel synthetic small molecule, effectively 
blocked DNMT in vitro and did not cause covalent enzyme 
trapping in human cell lines. Tumor cells treated with 
RG108 at a low concentration resulted in a significant DNA 
demethylation and TSGs reactivation (p16, SFRP1, secreted 
frizzled related protein-1, and TIMP-3) without detectable 
toxicity. RG108 also inhibited human tumor cell line 
(HCT116, NALM-6) proliferation and increased doubling 
time in culture. Intriguingly, RG108 did not affect the meth-
ylation of centromeric satellite sequences. These novel char-
acteristics made RG108 a promising DNMTi for modulation 
of epigenetic gene regulation [163]. 
  ncRNA is a class of novel useful DNMTi, such as an-
tisense RNA, short interference RNA (siRNA) and mi-
croRNA (miR). These DNMT targeting agents are comple-
mentary to mRNA of DNMT, induce degradation of the tar-
get transcripts and down regulate the DNMT expression 
[164,165]. Presently, many ncRNA have been demonstrated 
with demethylating ability, such as MG108, miR-29, 
DNMT-si (DNMT directing siRNA) [166,167,106].  
  Local anesthetic procaine and antiarrhythmic drug pro-
cainamide, the 4-Aminobezonic acid derivatives, have been 
shown demethylating activities in cellular assays and in 
mouse xenograft tumors [168,169], but the procaine must 
present at a high concentration to be an effective DNMTi in 
cell-free assays, and it has not been effective in all cell lines 
tested [170]. The psammaplins inhibit DNMT and HDAC 
activities in cell-free assays, thus should be evaluated further 
as both the DNMTi and HDACi [171]. 
  The other less characterized class of nucleoside DNMTi 
mainly contains procaine, procainamide and psammaplins 
[168,169,171]. Local anesthetic procaine and antiarrhythmic 
drug procainamide, the 4-Aminobezonic acid derivatives, 
have been shown demethylating activities in cellular assays 
and in mouse xenograft tumors [168,169], but the procaine 
must present at a high concentration to be an effective 
DNMTi in cell-free assays, and it has not been effective in 
all cell lines tested [170]. The psammaplins inhibit DNMT 
and HDAC activities in cell-free assays, thus should be 
evaluated further as both the DNMTi and HDACi [171]. 
5.5. DNMTi for Lung Cancer Therapy 
  The antitumor effect of 5-Aza-CR for lung cancer has 
been demonstrated by Belinsky et al. They found that low 
dose of 5-Aza-CR could decrease 30% of lung cancer inci-
dence, 50% might be achieved by 5-Aza-CR combined with 
HDACi sodium phenylbutyrate, which finding might provide 
a novel clinical strategy to help prevent lung cancer [110]. At 
the moment, the clinical phase I study of 5-Aza-CdR in 
combination with vaproic acid (VA) in patients with NSCLC 
is undergoing. And the results show great promise in 
NSCLC therapy [172]. 
  As 5-Aza-CR, most DNMTi were first studied in myelo-
dysplastic syndrome, and then were used for the solid tumor 
trials, therefore the development of DNMTi for lung cancer-
should take much longer than expected. The studies of 
DNMTi for lung cancer therapy are summerised in Table 2.  
  The L-selenomethionine, a nutrient demonstrated to re-
duce by half the incidence of expected lung cancer, may act 
partially through inhibition of DNMT [91,173]. And non-
steroidal anti-inflammatory drugs (NSAIDs) have been 
shown to exhibit potent anticancer effects in vitro and in 
vivo. Mithramycin A (MMA) is known to be a GC and CG-
rich DNA binding agent. Rou et al. found that this kind 
agent could serve as a DNMT1 inhibitor. When the highly 
metastatic CL1-5 lung cancer cells treated with MMA, the 
metastatic and invasion ability of the cell would be reduced, 
these results indicated a new agent for advanced lung cancer 
therapy [174]. Latterly, Pan et al. first demonstrated that 
NS398, a NSAID, would inhibit lung cancer cell invasion, 
and the mechanism was NS398 demethylating the secreted 
protein acidic and rich in cysteine (SPARC) gene in lung 
cancer [175]. 
  Antisense oligonucleotide was under clinical trails for 
lung cancer [176]. MG98 was an antisense oligonucleotide, 
which hybridized to the 3’-untranslated region (UTR) of 
DNMT1 mRNA and caused degradation of the transcript 
[15,177]. As an allosteric inhibitor, MG98 inhibit DNMT 
may also through the competition with the substrates for 
DNMT [166]. MG98 and siRNA directing to DNMT1 
mRNA induced lower DNMT1 level and reexpression of 
RASSF1A, CDKN2A in culture lung cancer CALU-6, and 
A549 cells have been demonstrated [101]. MiR-29 repre-
sents a class of naturally occurring small noncoding RNA 
molecules, which could bind to the 3’-UTR of target mRNAs 
and cause a block of translation [164]. The evidences that 
enhanced expression of MiR-29s in lung cancer cell lines 
A549 and H1299 restored normal silenced TSG, such as 
FHIT and WWOX, and inhibit tumorigenicity both in vitro 
and in vivo, resulted in a conclusion that expression of the 
MiR-29s (29a, 29b, 29c) was inversely correlated to 
DNMT3A and -B expression in lung cancer tissues and that 
MiR-29s directly target the 3’-UTRs of Dnmt3a and -3b 
[167]. Oridate et al. used siRNA to disrupt the expression of 
DNTM1 in human NSCLC A549 cells and found the de-
creased DNMT1 level was accompanied by suppression of 
cell proliferation and clone-forming ability. The mechanism 
of this may be due to the up-regulated cyclin dependent 
kinase inhibitor P21. Their study suggested that the siRNA 
approach could be used to disrupt effectively DNMT1 activ-
ity and lung cancer cell growth [168]. 346    Current Genomics, 2009, Vol. 10, No. 5  Tang et al. 
  Although the latest studies are concerned about the effect 
of demethylation on lung cancer, but one must be born in 
mind that down regulation of DNMT1 leads to a decrease in 
genomic instability [97]. In a mouse model for sarcomas, 
Dnmt1-deficient mice developed sarcomas at an earlier age 


























Fig. (5). Profile of lung tumorigenesis and medical prevention and therapies. 
A. Profile of lung tumorigenesis 
I: Carcinogens (such as tobacco components) stimulate certain signaling pathways in lung cells; 
II: DNMT expression induced by certain signaling pathway (e.g. Ras-Ap1); 
III: Up-regulated DNMT changes the normal methylation patterns; 
IV: With the help of other factors, the DNA methylation teams up with histone modification to cause the epigenetic alterations; 
V: Epigenetic regulation induces genetic changes (e.g. 3p deletion), gene silence (TSGs), certain cancer related signaling pathway alterations 
(Wnt); 
VI:Genetic alterations, signaling pathway change and gene silence is correlated & cooperated to disturb the proliferation-differentiation bal-
ance (assisting proliferation & blocking differentiation); 
VII: The non-arrest cell-cycle leads to the formation of tumor-like clones; 
VIII: The tumor-like clones turn into primary lung cancer;  
IX: The primary lung cancers begin to metastasis and transfer to other tissues. 
B. Steps are taken to prevent and/or treat lung cancer during lung tumorigenesis. 
I: Medical examination and prevention; 
II: The earlier detection, gene and others therapies; 
III: Diagnosis, surgery and treatments;  
IV: Diagnosis, therapies and palliative cares. Potential of DNMT and its Epigenetic Regulation  Current Genomics, 2009, Vol. 10, No. 5    347 
phic and a null allele of Dnmt1 developed aggressive T cell 
lymphomas [179]. However, some DNMT silenced genes 
may do well in the lung cancer therapy. Staub et al. reported 
that although DNMT induced HSulf-1 silence in ovarian 
cancer, but just this silenced Hsulf-1 sensitized the cancer to 
conventional first-line therapies. In this case, the DNMT 
played a positive role in therapy [180]. The potentially ad-
verse effects of DNA hypomethylation have led investigators 
to suggest that the most effective clinical use of DNMTi may 
be to combine these drugs, in a temporary and acute fashion, 
with secondary agents whose efficacy is enhanced by DNA 
hypomethylation [181]. Taken all data together, there were 
dual faces of DNMT, tumor induction and suppression, 
therefore when the DNMT is selected as therapeutic target. 
A fine equilibrium must be well done before a clinic trial is 
launched.  
6. CONCLUSION AND PERSPECTIVES 
  Epigenetic alterations are, at least, if not more important 
than genetic defects for the development and progression of 
lung cancer. In earlier days, it was thought, mistakenly, that 
alterations of DNA methylation occurred only as a result of 
cancerization. Because alternations of DNA methylation 
occur even in the precancerous stage before establishment of 
cancer and determine the clinicopathological characteristics 
of the developing malignancies. It is obvious that they are 
not a secondary result of cancerization. The role of DNMT-
mediated epigenetic alterations in lung cancer development 
has been the focus of increasing interest in recent years. 
These epigenetic abnormalities are present in almost all can-
cers and, alongside genetic changes, drive lung cancer pro-
gression [26].  
  A series of events occur during lung tumorigenesis and 
the corresponding medical actions taken are summarized in 
Fig. (5). Several breakthroughs have been achieved [2], es-
pecially in the DNA methylation and histone code realm. 
The proposals of epigenetic biomarker, epigenetic silencing, 
methylation profiling, histone coding, self-reinforcing epige-
netic cycle model, epigenomics, epigenetic profile, clearly 
reflect the intensive investigation on epigenetic regulation in 
lung tumorigenesis. Nevertheless, a number of key questions 
remain unanswered, such as the definite role of DNMTs in 
lung tumorigenesis; the role of other epigenetic regulations; 
the mechanism of DNA methylation ‘converses’ with other 
histone modification and reinforces suppression function 
mutually and the nature of DNMT targeting specific gene. 
Further studies about DNMT induced epigenetic regulation 
is needed, and will offer more perspectives in prevention, 
detection, diagnosis and post-treatment assessment of lung 
cancer and other malignancies. 
ABBREVIATIONS 
5-Aza-CR =  5-Aza-cytidine   
5-Aza-CdR  =  5-Aza-2’-deoxycytidine  
AC   =  Lung adenocarcinoma 
AML  =  Acute myeloid leukemia  
ATRA =  All-trans-retinoic  acid 
 
ATRX =  Cysteine alpha thalassemia retardation on 
the X rich zinc finger DNA binding motif 
BVES =  Blood vessel epicardial substance 
CAV1   =  Caveolin-1 
CDH1   =  E-cadherin 
CDH13   =  H-cadherin 
CDKN2A   =  P16/INK4a 
COMT   =  Catechol-o-methyltransferase 
DAP   =  Death-associated protein 
DAPK   =  Death-associated protein kinase 
DNMT   =  DNA methyltransferase 
DNMTi   =  DNA methyltransferase inhibitor 
EGCG   =  (-)-epigallocatechin-3-o-gallate 
FDA  =  Food and drug administration 
FHIT   =  Fragile histidine triad 
GADD45  =  Growth arrest and DNA damage inducible, 
alpha 
GK =  Gly-lys  sequence 
H3K4   =  H3 lysine 4 
HDAC   =  Histone deacetylase 
HDACi   =  Histone deacetylase inhibitor 
HKMT   =  Histone-lysine methyltransferase  
hsRBC  =  Human SRBC gene  
ING1  =  Inhibitor of Growth 1 
LSH   =  Lymphoid-specific helicase 
MBD   =  Methyl-CpG binding protein 
MDS =  Myelodysplastic  syndrome 
mCpG   =  Methyl-CpG site 
MeCP   =  Methyl CpG binding protein 
MGMT   =  O-6-methylguanine-DNA methyltransferase 
MiR   =  MicroRNAs 
MM   =  Malignant mesothelioma  
MMA =  Mithramycin  A 
NcRNA   =  Non-coding RNA 
NER  =  Nucleotide excision repair  
NLS  =  Nuclear localization signal sequence 
NSCLC   =  Non-small cell lung cancer  
PCNA   =  Proliferation cell nuclear antigen 
PDB =  Proliferating cell nuclear antigen binding 
domain 
PHD =  Polybromo homology domain 
PWWP   =  Pro-Trp-Trp-Pro tetrapeptide sequence 
RARB   =  Retinal acid receptor beta 
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RASSF   =  Ras association domain family 
rDNA   =  Ribosomal DNA 
rRNA   =  Ribosomal RNA 
SAH   =  S-adenosyl-L-homocysteine 
SAM   =  S-anenosyl-L-methionine 
SC   = Squamous  carcinoma 
SCLC   =  Small cell lung cancer 
siRNA =  Short  interference  RNA 
SPARC  =  Secreted protein acidic and rich in cysteine 
STK11 =  Serine/threonine  kinase 
TF   =  Transcription factors 
TRD  =  Aspartic acid transfer RNA 
TSG   =  Tumor suppressor gene 
VA =  Vaproic  acid 
UTR =  Untranslated  region 
WWOX =  WW domain containing oxidoreductase 
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